Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Suria Hamza	2. Issuer Name and Ticker or Trading Symbol ANAPTYSBIO, INC [ ANAB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President, CEO
(Last)          (First)          (Middle) C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210	3. Date of Earliest Transaction (MM/DD/YYYY) 11/4/2021
(Street) SAN DIEGO, CA 92121 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/4/2021		M		6059	A	$1.12	73695	D
Common Stock	11/4/2021		S(1)		6059	D	$35.00	67636	D
Common Stock	11/5/2021		M		14302	A	$1.12	81938	D
Common Stock	11/5/2021		S(1)		14302	D	$35.00	67636	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.12	11/4/2021		M			6059	(2)	12/8/2021	Common Stock	6059	$0.00	14302 (3)	D
Employee Stock Option (Right to Buy)	$1.12	11/5/2021		M			14302	(2)	12/8/2021	Common Stock	14302	$0.00	0 (3)	D

Explanation of Responses:
(1)	The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
(2)	The stock option grant was issued on December 9, 2011, is fully vested and exercisable until its expiration date of December 8, 2021.
(3)	In addition to the remaining options to purchase 0 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,155,538 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Suria Hamza C/O ANAPTYSBIO, INC. 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO, CA 92121	X		President, CEO

Signatures
/s/ Eric Loumeau, Attorney-in-Fact		11/5/2021
**Signature of Reporting Person		Date